The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis.

Jennifer SoungVivian LaquerJoseph F MerolaAngela MooreHany ElmaraghyChaoran HuMaria Lucia Buziqui PiruzeliEvangeline PierceEsther Garcia GilAbel D Jarell

Published in: Dermatology and therapy (2024)

ClinicalTrials.gov identifier NCT04626297.

Keyphrases

atopic dermatitis
immune response
high glucose
drug induced
diabetic rats
early onset
high intensity
toll like receptor
dendritic cells
inflammatory response
study protocol